A Randomized, Single-Blind, Placebo-Controlled, Multi-Centre, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Multiple Ascending Oral Doses of AZD1656 in Japanese T2DM Patients.
Phase of Trial: Phase I
Latest Information Update: 22 Dec 2016
At a glance
- Drugs AZD 1656 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms JMAD
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 04 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2009 Planned end date changed from 1 Nov 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov.